Randomized Phase 2 Trial of Abiraterone Acetate Plus Prednisone, Degarelix, or the Combination in Men with Biochemically Recurrent Prostate Cancer After Radical Prostatectomy.

Autio KA, Antonarakis ES, Mayer TM, Shevrin DH, Stein MN, Vaishampayan UN, Morris MJ, Slovin SF, Heath EI, Tagawa ST, Rathkopf DE, Milowsky MI, Harrison MR, Beer TM, Balar AV, Armstrong AJ, George DJ, Paller CJ, Apollo A, Danila DC, Graff JN, Nordquist L, Dayan Cohn ES, Tse K, Schreiber NA, Heller G, Scher HI

Open source

DOI: 10.1016/j.euros.2021.09.015
Published: 2021 Dec
Container: European urology open science
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/j.euros.2021.09.015,
  title = {Randomized Phase 2 Trial of Abiraterone Acetate Plus Prednisone, Degarelix, or the Combination in Men with Biochemically Recurrent Prostate Cancer After Radical Prostatectomy.},
  author = {Autio KA and Antonarakis ES and Mayer TM and Shevrin DH and Stein MN and Vaishampayan UN and Morris MJ and Slovin SF and Heath EI and Tagawa ST and Rathkopf DE and Milowsky MI and Harrison MR and Beer TM and Balar AV and Armstrong AJ and George DJ and Paller CJ and Apollo A and Danila DC and Graff JN and Nordquist L and Dayan Cohn ES and Tse K and Schreiber NA and Heller G and Scher HI},
  year = {2021},
  journal = {European urology open science},
  doi = {10.1016/j.euros.2021.09.015},
  url = {https://doi.org/10.1016/j.euros.2021.09.015}
}

RIS

TY  - JOUR
TI  - Randomized Phase 2 Trial of Abiraterone Acetate Plus Prednisone, Degarelix, or the Combination in Men with Biochemically Recurrent Prostate Cancer After Radical Prostatectomy.
AU  - Autio KA
AU  - Antonarakis ES
AU  - Mayer TM
AU  - Shevrin DH
AU  - Stein MN
AU  - Vaishampayan UN
AU  - Morris MJ
AU  - Slovin SF
AU  - Heath EI
AU  - Tagawa ST
AU  - Rathkopf DE
AU  - Milowsky MI
AU  - Harrison MR
AU  - Beer TM
AU  - Balar AV
AU  - Armstrong AJ
AU  - George DJ
AU  - Paller CJ
AU  - Apollo A
AU  - Danila DC
AU  - Graff JN
AU  - Nordquist L
AU  - Dayan Cohn ES
AU  - Tse K
AU  - Schreiber NA
AU  - Heller G
AU  - Scher HI
PY  - 2021
JO  - European urology open science
DO  - 10.1016/j.euros.2021.09.015
UR  - https://doi.org/10.1016/j.euros.2021.09.015
ER  -

APA

KA, A., ES, A., TM, M., DH, S., MN, S., UN, V., MJ, M., SF, S., EI, H., ST, T., DE, R., MI, M., MR, H., TM, B., AV, B., AJ, A., DJ, G., CJ, P., A, A., DC, D., JN, G., L, N., ES, D. C., K, T., NA, S., G, H., & HI, S. (2021). Randomized Phase 2 Trial of Abiraterone Acetate Plus Prednisone, Degarelix, or the Combination in Men with Biochemically Recurrent Prostate Cancer After Radical Prostatectomy.. European urology open science. https://doi.org/10.1016/j.euros.2021.09.015

Source records

pubmed · retrieved 2026-09-26T10:13:55.769Z